{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:02:11Z","timestamp":1761058931402},"reference-count":12,"publisher":"Informa Healthcare","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1517\/13543780902922678","type":"journal-article","created":{"date-parts":[[2009,5,9]],"date-time":"2009-05-09T12:29:24Z","timestamp":1241872164000},"page":"869-871","source":"Crossref","is-referenced-by-count":13,"title":["Mepolizumab for difficult-to-control asthma with persistent sputum eosinophilia"],"prefix":"10.1517","volume":"18","author":[{"given":"Sabina A","family":"Antoniu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3197","published-online":{"date-parts":[[2009,5,9]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199010113231505"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00029202"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.1.9703027"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.01.00229601"},{"key":"CIT0005","first-page":"980","volume":"7","author":"Antoniu","year":"2006","journal-title":"Curr Opin Investig Drugs"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200701-085OC"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808991"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805435"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.162.6.ats9-00"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03496-6"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00027302"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070812"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543780902922678","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T13:11:20Z","timestamp":1481634680000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543780902922678"}},"subtitle":["Evaluation of: Haldar P, Brightling CE, Hargadon B,<i>et al.<\/i>Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84Nair P, Pizzichini MM, Kjarsgaard M,<i>et al.<\/i>Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-93"],"short-title":[],"issued":{"date-parts":[[2009,5,9]]},"references-count":12,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2009,5,9]]},"published-print":{"date-parts":[[2009,6]]}},"alternative-id":["10.1517\/13543780902922678"],"URL":"https:\/\/doi.org\/10.1517\/13543780902922678","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,9]]}}}